Table 1.

Demonstration of combination, duration, and responses of treatment for patients

Case number	Combination of Drugs	Length of Treatment	Outcome
1	Colchicine + NSAID	2 years	Ineffectivity
	Colchicine + NSAID + anakinra	1 year	Flare of sacroiliitis
	Certolizumab + anakinra + colchicine	1 year	Psoriatic skin lesions related to anti-TNF drug
	Etanercept + anakinra + colchicine	1 week	First dose anaphylaxis related to etanercept
	Secukinumab + anakinra + colchicine	5 years	No adverse effects and complete remission
2	Colchicine + anakinra	2 years	Resistant amyloidosis and ineffectivity to sacroiliitis
	Colchicine + NSAID + anakinra	5 months	Progression of both diseases
	Interferon alpha 2B [IFN] + colchicine + NSAID	6 months	Ineffectivity
	Infliximab + colchicine + NSAID	6 months	Progression of both diseases
	Canakimumab + colchicine + NSAID	6 months	Secondary loss of response and progression of amyloidosis
	Canakimumab + tofacitinib + colchicine + NSAID	3 years	Secondary loss of response
	Tocilizumab + canakimumab + NSAID + colchicine	6 years	Complete remission
3	Colchicine + NSAID	1 year	Ineffectivity
	Colchicine + NSAID + sulphasalazine	1 year	Ineffectivity
	Etanercept + colchicine + NSAID	3 years	Secondary loss of response and progression of amyloidosis
	Anakinra + etanercept + colchicine + NSAID	2 years	Secondary loss of response and progression of amyloidosis
	Canakimumab + certolizumab + colchicine	1 year	Patient’s rejection of treatment
	Certolizumab + colchicine + on-demand anakinra	5 years	Complete remission
4	Anakinra + colchicine	4 years	Secondary loss of response
	Anakinra + colchicine + sulphasalazine	1 year	Progression of amyloidosis
	Anakinra + colchicine + sulphasalazine + tocilizumab	6 years	Complete remission

IFN, interferon; NSAID, Nonsteroid anti-inflammatory drug; TNF, tumor necrosis factor.